Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy
NCT06048289 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2023-09-25
Summary
A prospective, observational study to explore multidimensional biomarkers for predicting the efficacy of immunotherapy In biliary tract tumors
Conditions
- Biliary Tract Tumor
- Cholangiocarcinoma
Interventions
- OTHER
-
Blood samples, tumor biopsy specimens will be collected
Blood samples, tumor biopsy specimens at baseline will be collected
Sponsors & Collaborators
-
Zhejiang Cancer Hospital
lead OTHER
Principal Investigators
-
Biospecimen Retention Ying, Dr · Zhejiang Cancer Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-14
- Primary Completion
- 2024-03-31
- Completion
- 2025-03-31
Countries
- China
Study Locations
More Related Trials
-
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
NCT06006390 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
NCT05789498 ·Status: UNKNOWN
-
Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer
NCT05174156 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
NCT05172856 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
NCT05707910 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
NCT06532591 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
NCT06394427 ·Status: NOT_YET_RECRUITING
-
Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases
NCT05129202 ·Status: COMPLETED
-
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
NCT04866836 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
NCT06173219 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC
NCT06483009 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
NCT04924062 ·Status: COMPLETED ·Phase: PHASE3
-
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
NCT06790797 ·Status: RECRUITING
-
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study
NCT06241469 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
NCT05862259 ·Status: RECRUITING
-
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
NCT06010862 ·Status: RECRUITING ·Phase: PHASE1
-
The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma
NCT06647836 ·Status: ENROLLING_BY_INVITATION
-
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
NCT06586294 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05340491 ·Status: RECRUITING ·Phase: PHASE3
-
An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors
NCT05212896 ·Status: UNKNOWN ·Phase: PHASE1
-
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
NCT06080854 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
NCT05429697 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC
NCT06127329 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
NCT03930498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06145308 ·Status: RECRUITING ·Phase: PHASE2